Ablynx strengthens management team
This article was originally published in Scrip
Executive Summary
Ablynx, a Belgian biopharmaceutical company focused on the discovery and development of Nanobodies, a class of therapeutic proteins based on single-domain antibody fragments, has appointed Dr Debbie Law chief scientific officer. Dr Law was previously vice-president of research at PDL BioPharma, She has also held senior research positions with EOS Biotechnology and COR Therapeutics.